Fundraising FoxDementia Discovery Fund — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in
BoardAlicia Levey(Director)
Board seatNeil Weir· per SEC Form D · $66.6M raise · filed Nov 2025
Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesAlexandriaQiming HealthcareQiming Venture Partners USA
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsBrandon CapitalCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankDementia Discovery+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.